POPULATION PHARMACOKINETICS OF CYCLOSPORINE IN CLINICAL RENAL TRANSPLANT PATIENTS

Population pharmacokinetics of cyclosporine (CsA) in clinical renal transplant patients has been reported in the present study. A total of 2548 retrospective drug monitoring data points were collected from 120 renal transplant patients receiving CsA. Population modeling was performed using the NONMEM (nonlinear mixed-effect modeling) program, using a one-compartment model with first-order absorption and elimination. The final regression model for CsA clearance (CL/F) with the influence of six significant covariates, comprising postoperative days (POD), total bilirubin level (TBIL, micromolar concentration), current body weight (CBW, kilograms), age (years), concurrent metabolic inhibitors of cyclosporine (INHI), and hematocrit (HCT, percentage), has been established and expressed as CL/F = 28.5 – 1.24 · POD – 0.252 · (TBIL – 11) + 0.188 · (CBW – 58) –0.191 · (Age – 42) – 2.45 · INHI – 0.212 · (HCT – 28) (liters per hour). The values in parentheses represent the median level for each of the corresponding covariates. The population estimates for CL/F (28.5 l/h), V/F (volume of distribution, 133 l), and interpatient variability (CV% = 19.7%) for CL/F were achieved, respectively. The population model was further validated by internal and external approaches, and was demonstrated to be effective and stable. Moreover, simulation was conducted to facilitate the individualized treatment based on patient information and the final model.

[1]  B. Meibohm,et al.  The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients , 2003, Journal of clinical pharmacology.

[2]  B. Kasiske,et al.  The Effects of Calcium Channel Blockers on Cyclosporine and Its Metabolites in Renal Transplant Recipients , 1990, Therapeutic drug monitoring.

[3]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  A. Keogh,et al.  Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  G. Jiang,et al.  [Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM]. , 1995, Yao xue xue bao = Acta pharmaceutica Sinica.

[6]  G. Yee,et al.  Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Influence of age, obesity, and hematocrit. , 1988, Transplantation.

[7]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  W. Weimar,et al.  The use of cyclosporine in renal transplantation. , 2004, Transplantation proceedings.

[9]  M. Yacoub,et al.  Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  A. Domínguez-Gil,et al.  Valproate population pharmacokinetics in children , 1999, Journal of clinical pharmacy and therapeutics.

[11]  C A Prompt,et al.  [Cyclosporin A: drug interactions]. , 1991, AMB : revista da Associacao Medica Brasileira.

[12]  B. Kasiske,et al.  The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. , 1988, Transplantation.

[13]  V. Armstrong,et al.  New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. , 2001, Clinical biochemistry.

[14]  S. Mezzano,et al.  Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. , 1998, Transplantation proceedings.

[15]  R. Trompeter,et al.  Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral®) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption , 2003, Pediatric transplantation.

[16]  Toru Ishibashi,et al.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. , 2003, British journal of clinical pharmacology.

[17]  K. Lehle,et al.  First-pass metabolism of cyclosporine A in human intestine: inhibition by diltiazem. , 1998, Transplantation proceedings.

[18]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[19]  B. Charles,et al.  Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model , 2000, European Journal of Clinical Pharmacology.

[20]  Lewis B. Sheiner,et al.  Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[21]  J Parke,et al.  NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. , 1998, Therapeutic drug monitoring.

[22]  D. Abendroth.  Experience with therapeutic drug monitoring of cyclosporine. , 2004, Transplantation proceedings.

[23]  R. Morris,et al.  Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship. , 2003, British journal of clinical pharmacology.

[24]  P. Jacobson,et al.  Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.